Bliss gvs pharma Limited has strengthened its board governance by appointing two seasoned professionals as Independent Directors. The pharmaceutical company announced through a board resolution dated April 03, 2026, that it has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Non-Executive Independent Directors for five-year terms.

Board Resolution Details

The Board of Directors, acting on the recommendation of the Nomination and Remuneration Committee, passed resolutions by circulation on April 03, 2026. The company has informed both NSE and BSE about these key appointments through regulatory filings pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile of New Directors

Mr. Vijayanarayanan Mahadevan (DIN: 06639177)

Mr. Mahadevan brings extensive financial leadership experience spanning over 35 years across multiple organizations and geographies. As a Chartered Accountant, he has worked with prominent companies including Alcon, Sandoz, Novartis, and SHV Energy. His expertise encompasses:

• Establishing finance functions for new businesses across manufacturing, trading, and R&D environments
• Strategic financial leadership and effective project management
• Successfully turning around loss-making businesses into profitable operations
• Leading key remediation, restructuring, and regulatory initiatives
• Global recognition with teams acknowledged at APAC and international levels

Mr. Deepak Rameshchandra Shah (DIN: 06954206)

Mr. Shah is a Fellow Member of the Institute of Chartered Accountants of India (ICAI) with over 36 years of experience in taxation and audit. Based in Mumbai, he has held several key leadership positions:

• Former President of the Bombay Chartered Accountants' Society
• Former Chairman of the Western Zone of AIFTP
• Current Chairman of the Direct Taxation Committee of BCAS
• Independent Director on boards of The Ruby Mills Limited, Marathon Nextgen Realty Limited, and Siyaram Silk Mills Limited
• Contributor to professional literature

Regulatory Compliance

Both directors have been confirmed as not being debarred from holding director positions by SEBI or any other regulatory authority. The appointments comply with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, and related master circulars. Neither director has any relationships with existing directors of the company.

Next Steps

The company has approved the draft postal ballot notice to seek member approval for both appointments. The appointments will be effective for the full five-year term once shareholders provide their consent through the postal ballot process. The regulatory filing has been submitted to both NSE (Symbol: BLISSGVS) and BSE (Scrip Code: 506197) as required under listing obligations.

Bliss GVS Pharma Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with both the National Stock Exchange of India Limited and BSE Limited on April 02, 2026.

Certificate Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate dated April 01, 2026. The certificate confirms that securities received from depository participants for dematerialisation during Q4FY26 were properly processed and confirmed to the depositories.

Key Compliance Confirmations

The registrar's certificate validates several critical compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were properly mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within regulatory timelines

Corporate Communication

Company Secretary Aditi Bhatt signed the filing letter, ensuring proper corporate governance protocols were followed. The submission was also copied to National Securities Depository Limited and Central Depository Services (India) Ltd, maintaining transparency with all relevant depositories.

This quarterly filing demonstrates Bliss GVS Pharma's commitment to maintaining regulatory compliance and ensuring transparent securities management processes for investor protection.